Drug Profile
Talotrexin
Alternative Names: PT-523; TalvestaLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Ash Stevens; Dana-Farber Cancer Institute
- Developer Hana Biosciences
- Class Antineoplastics; Benzoic acids
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 09 Oct 2008 Discontinued - Phase-I for Solid tumours in USA (IV)
- 09 Oct 2008 Discontinued - Phase-II for Acute lymphoblastic leukaemia in USA (IV)
- 18 Dec 2006 Phase-II clinical trials in Acute lymphoblastic leukaemia in USA (IV-infusion)